News & Topics
News&Topics

2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

2012.12.27
Notice of Issuance of 1st Unsecured Convertible Bond with Stock Acquisition Rights and 29th Warrant by Third-Party Allotment
2012.12.27
Clinical Trial Notification Accepted by Japanese Regulatory Agency for SymBio's Phase I Oral Rigosertib (SyB C-1101) Trial in Frontline MDS
2012.11.09
SymBio Announces Revised Financial Forecast
2012.11.09
Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2012 [Japan GAAP] (Non-consolidated)
2012.10.24
SymBio Announces Completion of Patient Enrollment for Phase II Clinical Trial of SyB D-0701 in RINV
2012.09.20
Onconova Closes Deal with Baxter (BAX) for Rigosertib in Europe
2012.08.08
Financial Results for the Second Quarter of Fiscal Year Ending December 31, 2012 [Japan GAAP] (Non-consolidated)
2012.06.29
SymBio Initiates Japanese Phase I Trial of Rigosertib (SYB L-1101) in Relapsed/Refractory MDS
2012.06.14
SymBio Announces Orphan Drug Designation for TREAKISYM® (Bendamustine) in Chronic Lymphocytic Leukemia (CLL)
2012.06.04
SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits of TREAKISYM® (Bendamustine) in Combination with Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2012.06.01
SymBio Announces Data Presentations at 48th Annual American Society of Clinical Onoclogy Meeting
2012.05.30
SymBio Announces Development Status of TREAKISYM® in Refractory and Relapsed Aggressive Non-Hodgkin's Lymphoma
2012.05.15
Onconova Advances Oral Rigosertib to Phase II Clinical Trial in Myelodysplastic Syndromes
2012.05.11
Financial Results for the First Quarter of Fiscal Year Ended December 31, 2012 [Japan GAAP] (Non-consolidated)
2012.04.16
SymBio Announces Presentation at BioCentury Future Leaders in the Biotech Industry Conference
2012.03.29
Clinical Trial Notificaation Accepted for SymBio's Japan Phase 1 Trial of Rigosertib(SyB L-1101) in Refractory/Relapsed MDS
2012.03.09
7th Term General Shareholders' Meeting
2012.02.24
SymBio Announces Bendamustine Hydrochloride(SyB L-0501) Launch in Taiwan
2012.02.14
Summary of Financial Statements for the Fiscal Year Ended December 31, 2011 [Japan GAAP](Non-consolidated)